论文部分内容阅读
Purpose:To observe Fas expression change of cultured human retinal pigment epithelial (RPE) cells by IL-1β and TNF-α.Methods:With flow cytometry, immunohischemistry, and color imaging system, Fas expressions by exposure to IL-1β and/or TNF-α were measured.Results:The gray degree values of Fas expression were 67.5±6.1 in IL-1β+TNF-α-treated group, 80.1±9.2 in IL-1β-treated group, and 70.4±6.4 in TNF-α-treated group, respectively. There were significant differences (P < 0.005) compared with control group (107.0±10.2). Flow cytometry showed that 15.0% cultured human RPE cells expressed Fas. Fas-positive in IL-1β, TNF-α, and IL-1β+TNF-α-treated groups expressed was 28.1%, 34.5%, and 65.2%, respectively. Conclusion:IL-1β, TNF-α, and combining both of them can up-regulate Fas protein expression, which may contribute to more Fas (+) cells in proliferative vitreoretinopathy (PVR). Minimizing this process by means of inducing apoptosis of Fas (+) proliferative cells of Fas/FasL pathway is a future preventive and therapeutic possibility for PVR. Eye Science 2004;20:39-41.
Purpose: To observe Fas expression change of cultured human retinal pigment epithelial (RPE) cells by IL-1β and TNF-α. Methods: With flow cytometry, immunohischemistry, and color imaging system, Fas expressions by exposure to IL-1β and / or Results: The gray degree values of Fas expression were 67.5 ± 6.1 in IL-1β + TNF-α-treated group, 80.1 ± 9.2 in IL-1β-treated group, and 70.4 ± 6.4 in TNF- α There were significant differences (P <0.005) compared with control group (107.0 ± 10.2). Flow cytometry showed that 15.0% of cultured human RPE cells expressed Fas. Fas-positive in IL-1β, TNF- and IL-1β + TNF-α-treated groups expressed was 28.1%, 34.5%, and 65.2%, respectively. Conclusions: IL-1β, TNF-α, and combining both of them can up-regulate Fas protein expression, which may contribute to more Fas (+) cells in proliferative vitreoretinopathy (PVR). Minimizing this process by means of inducing apoptosis of Fas (+) proliferative cells of Fas / Fas L pathway is a future preventive and therapeutic possibility for PVR. Eye Science 2004; 20: 39-41.